MediPharm Labs Corp (OTCPK:MEDIF)

$ 0.0567 0.00265 (4.9%) Market Cap: 24.82 Mil Enterprise Value: 12.84 Mil PE Ratio: 0 PB Ratio: 0.71 GF Score: 0/100

Q1 2024 Medipharm Labs Corp Earnings Call Transcript
May 15, 2024

$0.0632 (+0.32%)

Earnings
Q4 2023 Medipharm Labs Corp Earnings Call Transcript
Mar 27, 2024

$0.0622 (-7.03%)

Earnings
Q3 2023 Medipharm Labs Corp Earnings Call Transcript
Nov 14, 2023

$0.0512 (-0.58%)

Earnings
Q2 2023 Medipharm Labs Corp Earnings Call Transcript
Aug 14, 2023

$0.0616 (-3.75%)

Earnings
Q1 2023 Medipharm Labs Corp Earnings Call Transcript
May 15, 2023

$0.057 (-2.06%)

Earnings
Q4 2022 Medipharm Labs Corp Earnings Call Transcript
Mar 31, 2023

$0.051 (-0.20%)

Earnings
Q3 2022 Medipharm Labs Corp Earnings Call Transcript
Nov 14, 2022

$0.0658 (+5.03%)

Earnings
Q2 2022 Medipharm Labs Corp Earnings Call Transcript
Aug 15, 2022

$0.0678 (-13.30%)

Earnings
Q1 2022 Medipharm Labs Corp Earnings Call Transcript
May 16, 2022

$0.07 (+4.17%)

Earnings
Q4 2021 Medipharm Labs Corp Earnings Call Transcript
Apr 01, 2022

$0.1346 (-9.66%)

Earnings
Q3 2021 Medipharm Labs Corp Earnings Call Transcript
Nov 15, 2021

$0.22 (-12.66%)

Earnings
Q2 2021 Medipharm Labs Corp Earnings Call Transcript
Aug 16, 2021

$0.2912 (-6.94%)

Earnings
Q1 2021 Medipharm Labs Corp Earnings Call Transcript
May 17, 2021

$0.3319 (-1.22%)

Earnings
Q4 2020 Medipharm Labs Corp Earnings Call Transcript
Mar 31, 2021

$0.3645 (+1.25%)

Earnings
Q3 2020 Medipharm Labs Corp Earnings Call Transcript
Nov 16, 2020

$0.415 (-28.32%)

Earnings
STADA Arzneimittel AG Enters Exclusive Medical Cannabis Partnership with MediPharm Labs Corp Investor Call Transcript
Oct 05, 2020
Q2 2020 Medipharm Labs Corp Earnings Call Transcript
Aug 13, 2020

$0.7693 (-0.62%)

Earnings
Q1 2020 Medipharm Labs Corp Earnings Call Transcript
Jun 18, 2020

$1.08 (-14.29%)

Earnings
Q4 2019 Medipharm Labs Corp Earnings Call Transcript
Apr 04, 2020

Earnings
Q4 2019 Medipharm Labs Corp Earnings Call Transcript
Mar 30, 2020

Earnings

Q3 2020 Medipharm Labs Corp Earnings Call Transcript

Nov 16, 2020 / 01:30PM GMT

Release Date Price: $0.415 (-28.32%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the MediPharm Labs third-quarter financial results earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Laura Lepore, Vice President, Investor Relations. Please go ahead, madam.

Laura Lepore

MediPharm Labs Corp. - VP, IR

Thank you, operator, and good morning, everyone. With me on the call today are Pat McCutcheon, Chief Executive Officer; Bobby Kwon, Chief Financial Officer; Warren Everitt, Chief Executive Officer, Asia-Pacific; and Keith Strachan, our President.

Before we begin, please note the following caution respecting forward-looking statements, which is made on behalf of MediPharm Labs and all of its representatives on this call. The statements made on this call will contain forward-looking information that involves risks and uncertainties, including those introduced by the COVID-19 pandemic. Actual results could differ

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.